Report #2824996

Received Feb 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: Oct 11, 2023
Onset: Oct 11, 2023
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

I had a dose of Shingrix on 10/25/2020 and a second on 10/11/203; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 25-OCT-2020). On 11-OCT-2023, the patient received the 2nd dose of Shingrix. On 11-OCT-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: I had a dose of Shingrix on 10/25/2020 and a second on 10/11/203). The outcome of the drug dose administration interval too long was unknown. Additional Information: GSK Receipt Date: 31-JAN-2025 The reporter reported that the patient received first dose on 25th October 2020 and second dose received on 11th October 2023, which led to drug dose administration interval too long.